Lupin Limited has informed the Exchange regarding a press release dated Jun 16, 2025, titled "Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement forTiotropium DPI in China".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Midcap 150 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has signed a license and supply agreement with China's Sino Universal Pharmaceuticals (SUP) to commercialize its Tiotropium Dry Powder Inhaler (18 mcg) in the Chinese market, used for treating chronic obstructive pulmonary disease (COPD). Under the deal, SUP will obtain regulatory approvals and handle sales in China, while Lupin will retain the marketing authorization and manufacture the product. This is Lupin's push to expand its respiratory portfolio into China, where COPD prevalence is rising. The product is already established for improving lung function and quality of life in respiratory patients.
This is a revenue-positive move as Lupin gains entry into the large Chinese respiratory market without bearing full commercialization or regulatory costs. However, the financial terms have not been disclosed, and the actual revenue contribution will depend on regulatory approval timelines in China and product uptake.